Corrections

Correction to
Lancet Neurol 2023;
22: 494–504
Furr Stimming E, Claassen DO, Kayson E,
et al. Safety and efficacy of valbenazine
for the treatment of chorea associated
with Huntington’s disease (KINECT-HD):
a phase 3, randomised, double-blind,
placebo-controlled trial. Lancet Neurol
2023; 22: 494–504—In this Article,
collaborator Bisena Bulica had been
omitted from the collaborator list at
the end of the paper. This correction
has been made to the online version as
of July 17, 2023.
Correction to
Lancet Neurol 2023; Published Online
22: 602–18 July 17, 2023
https://doi.org/10.1016/
S1474-4422(23)00279-X
Duering M, Biessels GJ, Brodtmann A,
et al. Neuroimaging standards for research Published Online
into small vessel disease—advances July 12, 2023
https://doi.org/10.1016/
since 2013. Lancet Neurol 2023; S1474-4422(23)00273-9
22: 602–18—In this Position Paper, an
error was made in the subsection on
terminology of incidental DWI-positive
lesion in the section on emerging SVD
features. In the second last sentence,
the text read “.. axial plane diameter of
20 mm or more”, it should have read “..
axial plane diameter of 20 mm or less.”
This correction has been made to the
online version as of July 12, 2023.

Correction to
Lancet Neurol 2023; Published Online
22: 578–90 July 20, 2023
https://doi.org/10.1016/
S1474-4422(23)00282-X
Granit V, Benatar M, Kurtoglu M, et al.
Safety and clinical activity of autologous
RNA chimeric antigen receptor T-cell
therapy in myasthenia gravis (MG-001):
a prospective, multicentre, open-label,
non-randomised phase 1b/2a study.
Lancet Neurol 2023; 22: 578–90—
In this Article, Marc H Feinberg’s
affiliation should have been “SFM
Clinical Research, Boca Raton, FL, USA”
and the MG-001 Study Team names
and affiliations have been corrected in
the appendix. These corrections have
been made to the online version as of
July 20, 2023.

www.thelancet.com/neurology Vol 22 September 2023 e10